Skip to content

A verification study of anti-obesity effects of the test food

A verification study of anti-obesity effects of the consumption of proteoglycan: An open-label trial - A verification study of anti-obesity effects of the consumption of proteoglycan

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000038688
Enrollment
15
Registered
2019-11-25
Start date
2019-11-26
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

Duration: Four weeks Test food: Powder containing proteoglycan Administration: Take one pack, once a day with dinner. * If you forget to take the test food, take it before going to bed.

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult subjects 2. Subjects who age between 20 and 59 when they provide written informed consent 3. Subjects between 22 kg/m2 or more and less than 30 kg/m2 in body mass index (BMI) 4. Subjects who are judged as eligible to participate in the study by the physician 5. Subjects who have relatively high Body fat percentage at screening (before consumption)

Exclusion criteria

Exclusion criteria: 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disease, kidney disease, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 5. Subjects who are currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, breast-feeding, and planning to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 9. Subjects who drink alcoholic beverages immoderately 10. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
Body fat percentage * Assess the measured value at screening (before consumption) and at four weeks after the start of test-food consumption and calculate the amount of change.

Secondary

MeasureTime frame
1. Body weight 2. Body Mass Index 3. Muscle mass 4. Lean body mass 5. Abdominal circumference 6. Japanese Knee Osteoarthritis Measure (JKOM) 6-1. The score of visual analogue scale; VAS 6-2. The total score 6-3. The score of pain and stiffness in knees 6-4. The score of condition in daily life 6-5. The score of general activities 6-6. The score of health conditions 6-7. Individual items of the JKOM questionnaire 7. MOS Short-Form 36-Item Health Survey (SF-36) 7-1. Physical component summary (PCS) 7-2. Mental component summary (MCS) 7-3. Role/Social component summary (RCS) 7-4. Physical functioning 7-5. Role physical 7-6. Bodily pain 7-7. General health 7-8. Vitality 7-9. Social functioning 7-10. Role emotional 7-11. Mental health 8. The total score of Pittsburgh Sleep Quality Index, Japanese version (PSQI-J) 9. Specific IgE (cedar pollen, cypress pollen, Dermatophagoides pteronyssinus and house dust) * 1-5, 7-9 Assess the measured value at screening (before consumption) and at four weeks after the start of test-food consumption and calculate the amount of change. * 6 Measured at screening (before consumption) and at four weeks after the start of test-food consumption.

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026